- Report
- March 2024
- 181 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- December 2023
- 130 Pages
Global
From €5730EUR$5,950USD£4,928GBP
- Report
- May 2024
- 196 Pages
Global
From €5248EUR$5,450USD£4,514GBP
- Report
- November 2023
- 185 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Drug Pipelines
- February 2024
- 80 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Drug Pipelines
- December 2022
- 100 Pages
Global
From €2648EUR$2,750USD£2,278GBP
- Report
- August 2022
- 117 Pages
Global
From €4334EUR$4,500USD£3,727GBP
- Report
- February 2024
- 102 Pages
Global
From €3500EUR$3,893USD£3,115GBP
- Report
- May 2022
- 92 Pages
Global
From €3500EUR$3,893USD£3,115GBP
- Report
- November 2021
- 620 Pages
Global
From €3852EUR$4,000USD£3,313GBP
- Report
- March 2020
- 194 Pages
Global
From €5171EUR$5,370USD£4,448GBP
Peramivir is an antiviral drug used to treat a variety of infectious diseases. It is a neuraminidase inhibitor, meaning it works by blocking the activity of the neuraminidase enzyme, which is essential for the spread of the virus within the body. Peramivir is used to treat influenza, including both seasonal and pandemic strains, as well as other viral infections such as respiratory syncytial virus (RSV). It is administered intravenously and is generally well tolerated, with few side effects.
Peramivir is approved for use in several countries, including the United States, Japan, and South Korea. It is also available in some countries as an investigational drug. In the United States, it is approved for use in adults and children over two years of age.
The market for Peramivir is growing as the need for effective treatments for infectious diseases increases. It is a promising drug for the treatment of influenza and other viral infections, and its use is likely to expand in the future.
Companies in the Peramivir market include Shionogi & Co., Ltd., BioCryst Pharmaceuticals, Inc., and Daewoong Pharmaceutical Co., Ltd. Show Less Read more